CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma
. . Slik K, Turkki R, Carpén O, Kurki S, Korkeila E, Sundström J, Pellinen T. . Am J Surg Pathol. 2019 Nov;43(11):1473-1482. doi: 10.1097/PAS.0000000000001356. Abstract Current risk factors in stage II colorectal carcinoma are insufficient to guide treatment decisions. Loss of CDX2 has been shown to associate with poor clinical outcome and predict benefit …